Company: Aurobindo Pharma Ltd. Category: Result Analysis


NULL
May 29, 2019, 10:46 a.m.
Publisher: moneycontrol.com

NULL
Feb. 8, 2019, 11:04 a.m.
Publisher: moneycontrol.com

Net Sales are expected to increase by 15.8 percent Y-o-Y (up 5.7 percent Q-o-Q) to Rs. 5,022.3 crore, according to ICICI Direct.
Jan. 11, 2019, 5:23 p.m.
Publisher: moneycontrol.com

For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.
Jan. 4, 2019, 10:45 a.m.
Publisher: moneycontrol.com


For 2QFY2019, Aurobindo Pharma (APL), the company posted sales of Rs. 4,667cr v/s. Rs. 4,354cr in 2QFY2018, a yoy growth of 7.2%. On the operating front, the EBITDA margin came in at 18.8% v/s. 23.8% in 2QFY2018.
Nov. 17, 2018, 10:54 a.m.

ARBP’s performance in Q2FY19 were in-line with our estimates as its net sales, adj. EBITDA and PAT increased by 12%, 33% and 34% QoQ respectively.
Nov. 13, 2018, 11:20 a.m.
Publisher: plindia.com

Aurobindo Pharma’s (APL) 2QFY19 revenues (Rs47,514mn) were 9.6%/4.4% above our/consensus estimates, respectively.
Nov. 13, 2018, 11:18 a.m.
Publisher: nirmalbang.com

Aurobindo Pharma (ARBP) has delivered a better-than-expected performance on all metrics in 2QFY19.
Nov. 13, 2018, 11:10 a.m.
Publisher: trade.rsec.co.in

NULL
Nov. 12, 2018, 7:17 p.m.
Publisher: moneycontrol.com

The earnings before interest, taxes, depreciation and amortization was reported at Rs 986.3 crore for the September quarter.
Nov. 12, 2018, 7:07 p.m.
Publisher: moneycontrol.com

-->